FDA clears Formosa’s eye drop for postsurgical pain, inflammation March 5, 2024 By Marian (YoonJee) Chu Taiwan’s Formosa Pharmaceuticals Inc. and Aimmax Therapeutics, Inc. said the U.S. FDA approved APP-13007 (clobetasol propionate ophthalmic suspension 0.05%), a twice-daily corticosteroid eye drop for postoperative eye pain and inflammation.Read More
